2024-08-012024-12-312024-12-31false14212968ORFONYX BIO LTD2025-08-18falseiso4217:GBPxbrli:pure142129682024-07-31142129682024-12-31142129682024-08-012024-12-31142129682023-07-31142129682024-07-31142129682023-08-012024-07-3114212968bus:SmallEntities2024-08-012024-12-3114212968bus:AuditExempt-NoAccountantsReport2024-08-012024-12-3114212968bus:FullAccounts2024-08-012024-12-3114212968bus:PrivateLimitedCompanyLtd2024-08-012024-12-3114212968core:WithinOneYear2024-12-3114212968core:AfterOneYear2024-12-3114212968core:WithinOneYear2024-07-3114212968core:AfterOneYear2024-07-3114212968core:ShareCapital2024-12-3114212968core:SharePremium2024-12-3114212968core:RevaluationReserve2024-12-3114212968core:OtherReservesSubtotal2024-12-3114212968core:RetainedEarningsAccumulatedLosses2024-12-3114212968core:ShareCapital2024-07-3114212968core:SharePremium2024-07-3114212968core:RevaluationReserve2024-07-3114212968core:OtherReservesSubtotal2024-07-3114212968core:RetainedEarningsAccumulatedLosses2024-07-3114212968core:LandBuildings2024-12-3114212968core:PlantMachinery2024-12-3114212968core:Vehicles2024-12-3114212968core:FurnitureFittings2024-12-3114212968core:OfficeEquipment2024-12-3114212968core:NetGoodwill2024-12-3114212968core:IntangibleAssetsOtherThanGoodwill2024-12-3114212968core:ListedExchangeTraded2024-12-3114212968core:UnlistedNon-exchangeTraded2024-12-3114212968core:LandBuildings2024-07-3114212968core:PlantMachinery2024-07-3114212968core:Vehicles2024-07-3114212968core:FurnitureFittings2024-07-3114212968core:OfficeEquipment2024-07-3114212968core:NetGoodwill2024-07-3114212968core:IntangibleAssetsOtherThanGoodwill2024-07-3114212968core:ListedExchangeTraded2024-07-3114212968core:UnlistedNon-exchangeTraded2024-07-3114212968core:LandBuildings2024-08-012024-12-3114212968core:PlantMachinery2024-08-012024-12-3114212968core:Vehicles2024-08-012024-12-3114212968core:FurnitureFittings2024-08-012024-12-3114212968core:OfficeEquipment2024-08-012024-12-3114212968core:NetGoodwill2024-08-012024-12-3114212968core:IntangibleAssetsOtherThanGoodwill2024-08-012024-12-3114212968core:ListedExchangeTraded2024-08-012024-12-3114212968core:UnlistedNon-exchangeTraded2024-08-012024-12-3114212968core:MoreThanFiveYears2024-08-012024-12-3114212968core:Non-currentFinancialInstruments2024-12-3114212968core:Non-currentFinancialInstruments2024-07-3114212968dpl:CostSales2024-08-012024-12-3114212968dpl:DistributionCosts2024-08-012024-12-3114212968core:LandBuildings2024-08-012024-12-3114212968core:PlantMachinery2024-08-012024-12-3114212968core:Vehicles2024-08-012024-12-3114212968core:FurnitureFittings2024-08-012024-12-3114212968core:OfficeEquipment2024-08-012024-12-3114212968dpl:AdministrativeExpenses2024-08-012024-12-3114212968core:NetGoodwill2024-08-012024-12-3114212968core:IntangibleAssetsOtherThanGoodwill2024-08-012024-12-3114212968dpl:GroupUndertakings2024-08-012024-12-3114212968dpl:ParticipatingInterests2024-08-012024-12-3114212968dpl:GroupUndertakingscore:ListedExchangeTraded2024-08-012024-12-3114212968core:ListedExchangeTraded2024-08-012024-12-3114212968dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-08-012024-12-3114212968core:UnlistedNon-exchangeTraded2024-08-012024-12-3114212968dpl:CostSales2023-08-012024-07-3114212968dpl:DistributionCosts2023-08-012024-07-3114212968core:LandBuildings2023-08-012024-07-3114212968core:PlantMachinery2023-08-012024-07-3114212968core:Vehicles2023-08-012024-07-3114212968core:FurnitureFittings2023-08-012024-07-3114212968core:OfficeEquipment2023-08-012024-07-3114212968dpl:AdministrativeExpenses2023-08-012024-07-3114212968core:NetGoodwill2023-08-012024-07-3114212968core:IntangibleAssetsOtherThanGoodwill2023-08-012024-07-3114212968dpl:GroupUndertakings2023-08-012024-07-3114212968dpl:ParticipatingInterests2023-08-012024-07-3114212968dpl:GroupUndertakingscore:ListedExchangeTraded2023-08-012024-07-3114212968core:ListedExchangeTraded2023-08-012024-07-3114212968dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-08-012024-07-3114212968core:UnlistedNon-exchangeTraded2023-08-012024-07-3114212968core:NetGoodwill2024-12-3114212968core:IntangibleAssetsOtherThanGoodwill2024-12-3114212968core:LandBuildings2024-12-3114212968core:PlantMachinery2024-12-3114212968core:Vehicles2024-12-3114212968core:FurnitureFittings2024-12-3114212968core:OfficeEquipment2024-12-3114212968core:AfterOneYear2024-12-3114212968core:WithinOneYear2024-12-3114212968core:ListedExchangeTraded2024-12-3114212968core:UnlistedNon-exchangeTraded2024-12-3114212968core:ShareCapital2024-12-3114212968core:SharePremium2024-12-3114212968core:RevaluationReserve2024-12-3114212968core:OtherReservesSubtotal2024-12-3114212968core:RetainedEarningsAccumulatedLosses2024-12-3114212968core:NetGoodwill2024-07-3114212968core:IntangibleAssetsOtherThanGoodwill2024-07-3114212968core:LandBuildings2024-07-3114212968core:PlantMachinery2024-07-3114212968core:Vehicles2024-07-3114212968core:FurnitureFittings2024-07-3114212968core:OfficeEquipment2024-07-3114212968core:AfterOneYear2024-07-3114212968core:WithinOneYear2024-07-3114212968core:ListedExchangeTraded2024-07-3114212968core:UnlistedNon-exchangeTraded2024-07-3114212968core:ShareCapital2024-07-3114212968core:SharePremium2024-07-3114212968core:RevaluationReserve2024-07-3114212968core:OtherReservesSubtotal2024-07-3114212968core:RetainedEarningsAccumulatedLosses2024-07-3114212968core:NetGoodwill2023-07-3114212968core:IntangibleAssetsOtherThanGoodwill2023-07-3114212968core:LandBuildings2023-07-3114212968core:PlantMachinery2023-07-3114212968core:Vehicles2023-07-3114212968core:FurnitureFittings2023-07-3114212968core:OfficeEquipment2023-07-3114212968core:AfterOneYear2023-07-3114212968core:WithinOneYear2023-07-3114212968core:ListedExchangeTraded2023-07-3114212968core:UnlistedNon-exchangeTraded2023-07-3114212968core:ShareCapital2023-07-3114212968core:SharePremium2023-07-3114212968core:RevaluationReserve2023-07-3114212968core:OtherReservesSubtotal2023-07-3114212968core:RetainedEarningsAccumulatedLosses2023-07-3114212968core:AfterOneYear2024-08-012024-12-3114212968core:WithinOneYear2024-08-012024-12-3114212968core:Non-currentFinancialInstrumentscore:CostValuation2024-08-012024-12-3114212968core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-08-012024-12-3114212968core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-08-012024-12-3114212968core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-08-012024-12-3114212968core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-08-012024-12-3114212968core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-08-012024-12-3114212968core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-08-012024-12-3114212968core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-08-012024-12-3114212968core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-08-012024-12-3114212968core:Non-currentFinancialInstrumentscore:CostValuation2024-12-3114212968core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-12-3114212968core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-12-3114212968core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-12-3114212968core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-12-3114212968core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-12-3114212968core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-12-3114212968core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-12-3114212968core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-12-3114212968core:Non-currentFinancialInstrumentscore:CostValuation2024-07-3114212968core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-07-3114212968core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-07-3114212968core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-07-3114212968core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-07-3114212968core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-07-3114212968core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-07-3114212968core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-07-3114212968core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-07-3114212968bus:Director12024-08-012024-12-3114212968bus:Director22024-08-012024-12-3114212968bus:Director32024-08-012024-12-3114212968bus:Director42024-08-012024-12-31

ORFONYX BIO LTD

Registered Number
14212968
(England and Wales)

Unaudited Financial Statements for the Period ended
31 December 2024

ORFONYX BIO LTD
Company Information
for the period from 1 August 2024 to 31 December 2024

Directors

BROWN, Claire, Dr
DARUNII DE JONGH, Lisanne
MENN, Benedicte
WOOD, Matthew John Andrew, Prof

Company Secretary

STEPHENS, Benedict Charles

Registered Address

Bioescalator Innovation Building
Roosevelt Drive
Oxford
OX3 7FZ

Registered Number

14212968 (England and Wales)
ORFONYX BIO LTD
Balance Sheet as at
31 December 2024

Notes

31 Dec 2024

31 Jul 2024

£

£

£

£

Fixed assets
Tangible assets3206,945221,261
206,945221,261
Current assets
Debtors276,064269,017
Cash at bank and on hand494,1911,227,485
770,2551,496,502
Creditors amounts falling due within one year4(130,603)(177,768)
Net current assets (liabilities)639,6521,318,734
Total assets less current liabilities846,5971,539,995
Net assets846,5971,539,995
Capital and reserves
Called up share capital3,078,5933,078,593
Profit and loss account(2,231,996)(1,538,598)
Shareholders' funds846,5971,539,995
The financial statements were approved and authorised for issue by the Board of Directors on 18 August 2025, and are signed on its behalf by:
BROWN, Claire, Dr
Director
Registered Company No. 14212968
ORFONYX BIO LTD
Notes to the Financial Statements
for the period ended 31 December 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Going concern
The accounts have been prepared on a going concern basis which assumes that the company will be able to continue to meet its financial obligations for a period of at least 12 months from the date of this report. In deciding that this basis was appropriate, the directors considered their cash flow forecasts and the likelihood of securing new investment if and as required.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:
Trade and other creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
2.Average number of employees

20242024
Average number of employees during the year64
3.Tangible fixed assets

Plant & machinery

Office Equipment

Total

£££
Cost or valuation
At 01 August 24249,18812,807261,995
Additions22,0441,50023,544
At 31 December 24271,23214,307285,539
Depreciation and impairment
At 01 August 2438,8301,90440,734
Charge for year36,6121,24837,860
At 31 December 2475,4423,15278,594
Net book value
At 31 December 24195,79011,155206,945
At 31 July 24210,35810,903221,261
4.Creditors: amounts due within one year

2024

2024

££
Trade creditors / trade payables20,35894,195
Taxation and social security12,56712,566
Other creditors64,38737,999
Accrued liabilities and deferred income33,29133,008
Total130,603177,768